Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease Meeting Abstract

  

Authors:	Cortés, J.; Rugo, H. S.; Tolaney, S. M.; Diéras, V.; Patt, D.; Wildiers, H.; Nanda, S.; Koustenis, A.; Dickler, M. N.; Baselga, J.
Abstract Title:	Analysis of overall survival by tumor response in MONARCH 1, a phase 2 study of abemaciclib, a CDK4 and CDK6 inhibitor, in women with HR+/HER2- metastatic breast cancer (MBC) after chemotherapy for advanced disease
Meeting Title:	42nd ESMO Congress (ESMO 2017)
Journal Title:	Annals of Oncology
Volume:	28
Issue:	Suppl. 5
Meeting Dates:	2017 Sep 8-12
Meeting Location:	Madrid, Spain
ISSN:	0923-7534
Publisher:	Oxford University Press
Date Published:	2017-09-01
Start Page:	mdx365.012
Language:	English
ACCESSION:	WOS:000411324000238
PROVIDER:	wos
DOI:	10.1093/annonc/mdx365.012
Notes:	Meeting Abstract: 249P -- Appears on page 80 of the abstract book -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/116996